Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | galactosidase, alpha | Starlite/ChEMBL | No references |
Homo sapiens | lysine (K)-specific demethylase 4E | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | alpha-galactosidase/alpha-N-acetylgalactosaminidase, putative | 0.0082 | 0.2176 | 0.5 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0124 | 1 | 1 |
Echinococcus multilocularis | Glycoside hydrolase, family 27 | 0.0124 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 0.2176 | 1 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0082 | 0.2176 | 0.2176 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0124 | 1 | 1 |
Toxoplasma gondii | melibiase subfamily protein | 0.0124 | 1 | 0.5 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0124 | 1 | 1 |
Echinococcus multilocularis | Alpha N acetylgalactosaminidase | 0.0124 | 1 | 1 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0124 | 1 | 1 |
Brugia malayi | Melibiase family protein | 0.0082 | 0.2176 | 1 |
Schistosoma mansoni | alpha-galactosidase/alpha-n-acetylgalactosaminidase | 0.0082 | 0.2176 | 0.2176 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.9285 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 1.122 uM | PubChem BioAssay. qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 5.0119 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium. (Class of assay: confirmatory) [Related pubchem assays: 901 ] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase). (Class of assay: confirmatory) [Related pubchem assays: 2429 (Confirmation qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2407 (Probe Development Summary for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)), 2427 (Thermal Shift Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of L3MBTL1. (Class of assay: confirmatory) [Related pubchem assays: 485292 (Probe Development Summary for Inhibitors of L3MBTL1)] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.